KNSA (Kiniksa Pharmaceuticals International, plc) PDUFA Date

Jul 23, 2026

Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026

Kiniksa Pharmaceuticals International will hold a conference call on July 28, 2026, to discuss its second quarter financial results and recent developments. The call will be accessible via webcast and telephone, with a replay available shortly after. The company focuses on developing therapies for unmet medical needs, particularly in cardiovascular indications.

Jun 1, 2026

Kiniksa Pharmaceuticals to Present at Upcoming June 2026 Investor Conferences

Kiniksa Pharmaceuticals has announced its participation in investor conferences scheduled for June 2026. Management will engage in fireside chats, providing insights into the company's strategies and developments. The presentations will be accessible via live webcast, with replays available shortly after the events. This initiative underscores Kiniksa's commitment to transparency and investor relations.

May 29, 2026

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced its participation in upcoming investor conferences, including the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference. Management will conduct fireside chats, allowing for insights into the company’s strategies and offerings. Webcasts of the presentations will be available on the company’s website, ensuring stakeholders have access to key information.

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals reported strong financial results for Q1 2026, with ARCALYST net product revenue reaching $214.3 million, a 56% increase from the previous year. The company raised its revenue guidance for ARCALYST to between $930 million and $945 million for the year. Additionally, KPL-387 Phase 2 data is expected in the second half of 2026, with a Phase 3 trial initiation planned by year-end.

Apr 23, 2026

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

Kiniksa Pharmaceuticals International, plc will report its first quarter 2026 financial results on April 28, 2026. The company will host a conference call and live webcast at 8:30 a.m. Eastern Time. Participants can register for the call and access a replay afterward. Kiniksa focuses on developing therapies for unmet medical needs.

Apr 8, 2026

Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST (rilonacept) in Recurrent Pericarditis

Kiniksa Pharmaceuticals has launched a Direct-to-Consumer campaign called Heart’s Home, aimed at raising awareness about recurrent pericarditis and promoting their FDA-approved therapy ARCALYST. This initiative emphasizes the importance of patient education and encourages those suffering from this condition to engage in discussions with their healthcare providers about potential treatments. The campaign leverages multiple media channels, highlighting the significant impact recurrent pericarditis has on patients' lives. ARCALYST stands out as the only therapy approved specifically for the treatment and recurrence prevention of this condition.

Feb 26, 2026

Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference

Kiniksa Pharmaceuticals will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. The presentation will be accessible via a live webcast, with a replay available shortly after. This event underscores Kiniksa's focus on improving patient outcomes through novel therapies.

Feb 24, 2026

▼ -8.2%on this newsshared move

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals reported strong financial results for Q4 and the full year 2025, with ARCALYST achieving $677.6 million in revenue. The company anticipates 2026 sales for ARCALYST to reach between $900 and $920 million. KPL-387's Phase 2 data is expected in the second half of 2026, and a Phase 1 trial for KPL-1161 is set to begin by the end of 2026. Kiniksa's financial position supports ongoing investments in its portfolio.

Feb 19, 2026

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Kiniksa Pharmaceuticals International, plc (KNSA) will host a conference call on February 24, 2026, to discuss its financial results for the fourth quarter and full year 2025. The call will be accessible via a live webcast on the company's website. Participants can register to join the conference call by telephone, receiving a confirmation email with details. Kiniksa focuses on developing treatments for diseases with unmet needs, especially in the cardiovascular sector.

Jan 12, 2026

Kiniksa Pharmaceuticals Provides Corporate Update

Kiniksa Pharmaceuticals has reported significant growth in net product revenue for ARCALYST, which reached $677.5 million in 2025, marking a 62% increase from the previous year. The company projects that ARCALYST will generate between $900 million and $920 million in 2026. Kiniksa is advancing its pipeline with KPL-387, with data expected in 2026, and plans to initiate a Phase 1 trial for KPL-1161 by year-end. The company's strong cash balance of $414.1 million positions it well for future developments and initiatives.

Jan 12, 2026

Kiniksa Pharmaceuticals Provides Corporate Update - ARCALYST (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth - - ARCALYST 2026 net product revenue expected to

Kiniksa Pharmaceuticals has reported a significant growth in net product revenue for ARCALYST, reaching $677.5 million in 2025, representing a 62% year-over-year increase. Looking ahead, the company anticipates ARCALYST revenue to range between $900 million and $920 million in 2026. Additionally, Kiniksa is in a strong financial position with a cash balance of $414.1 million as of the end of 2025. The company is also advancing its clinical trials for KPL-387 and KPL-1161, which could enhance treatment options for recurrent pericarditis patients.

Jan 7, 2026

Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced its participation in the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 12, 2026. During the conference, Kiniksa will present at 2:15 p.m. Pacific Time. A live webcast of the presentation will be available on the company’s website, with a replay accessible within 48 hours post-event. Kiniksa is focused on developing therapies for diseases with unmet needs, particularly in the cardiovascular sector.

Nov 12, 2025

Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

Kiniksa Pharmaceuticals will present at the Jefferies Global Healthcare Conference in London on November 17, 2025. The presentation will be accessible via a live webcast on the company's website, with a replay available shortly after. Kiniksa is dedicated to developing therapies for unmet medical needs, particularly in cardiovascular indications.

Oct 28, 2025

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals reported strong financial results for Q3 2025, with ARCALYST net product revenue reaching $180.9 million, a 61% increase year-over-year. The company raised its revenue guidance for ARCALYST to between $670 million and $675 million. Additionally, KPL-387 received Orphan Drug Designation, and the company is on track for data from its Phase 2/3 trial in 2026.

Oct 23, 2025

Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025

Kiniksa Pharmaceuticals International, plc (KNSA) announced a conference call scheduled for October 28, 2025, to discuss its third quarter financial results. The call will include a live webcast accessible through the company’s website and will offer interaction opportunities for investors. The company emphasizes its focus on developing therapies for unmet medical needs, particularly in cardiovascular indications.

Oct 17, 2025

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis

Kiniksa Pharmaceuticals has received Orphan Drug Designation from the FDA for KPL-387, aimed at treating pericarditis, including recurrent cases. This monoclonal antibody targets IL-1R1, potentially allowing for convenient monthly self-injections. Data from the ongoing Phase 2/3 trial is expected in late 2026, highlighting Kiniksa's commitment to addressing rare diseases.

Sep 3, 2025

Corporate Presentation SEPTEMBER 2025 Forward Looking Statements 2 This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements with re

The corporate presentation outlines the ongoing investigation of KPL-387, focusing on its application for recurrent pericarditis treatment. A Phase 2 trial is assessing KPL-387’s efficacy and safety, involving up to 80 participants who have had limited success with conventional therapies. The study emphasizes the goal of transitioning patients to KPL-387 monotherapy, with preliminary endpoints focusing on treatment response and time to recurrence. A long-term extension to monitor results for up to 24 months is also detailed.

Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution - ARCALYST (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth - - ARCAL

Kiniksa Pharmaceuticals reported strong financial results for Q2 2025, with ARCALYST achieving net product revenue of $156.8 million, marking a 52% increase year-over-year. The company has raised its 2025 sales guidance for ARCALYST to between $625 and $640 million. Additionally, Kiniksa has initiated a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, expecting data in the second half of 2026. The positive financial performance and portfolio execution highlight Kiniksa's robust position in the biopharmaceutical market.

Jul 24, 2025

Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025

Kiniksa Pharmaceuticals International, plc will hold a conference call on July 29, 2025, to discuss its second quarter financial results and recent portfolio developments. The call will be accessible via a live webcast and telephone registration. A replay will be available shortly after the event.

Jun 5, 2025

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

Kiniksa Pharmaceuticals announced the planned Phase 2/3 clinical trial for KPL-387, targeting recurrent pericarditis. The trial is set to begin in mid-2025, with Phase 2 data expected in the second half of 2026. KPL-387 is designed for monthly subcutaneous dosing, potentially enhancing treatment options for patients.

Apr 30, 2025

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

Kiniksa Pharmaceuticals has partnered with Carly Pearce to promote awareness of recurrent pericarditis through the Life DisRPted campaign. Pearce, diagnosed with the condition, shares her journey to encourage self-advocacy among patients. The campaign aims to educate about the disease's symptoms and the importance of early diagnosis to improve patient quality of life.

Apr 29, 2025

▲ +20.5%on this newsshared move

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution - ARCALYST (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth - - ARCALY

Kiniksa Pharmaceuticals reported robust financial results for Q1 2025, achieving $137.8 million in net product revenue from ARCALYST, which reflects a 75% increase compared to the previous year. The company has raised its revenue guidance for the full year, expecting sales between $590 million and $605 million. Additionally, Kiniksa plans to initiate a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data anticipated in the second half of 2026. The company's focus remains on delivering novel therapies for diseases with unmet needs, particularly in cardiovascular medicine.

Apr 24, 2025

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced it will hold a conference call on April 29, 2025, at 8:30 a.m. Eastern Time to present its first quarter 2025 financial results and recent developments. The conference call will be accessible via a live webcast on the company's website, with registration available for telephone participants. Kiniksa is dedicated to developing therapeutic solutions for diseases with significant unmet needs, particularly in the cardiovascular domain.

Feb 25, 2025

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution - ARCALYST (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 milli

Kiniksa Pharmaceuticals has reported its fourth quarter and full year 2024 financial results, showcasing a significant net product revenue of $417 million for ARCALYST. The company anticipates a continued upward trajectory, expecting 2025 revenues to fall between $560 and $580 million. Future growth is additionally supported by the planned initiation of a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis slated for mid-2025, although the company will discontinue the development of abiprubart for Sjögren's Disease. Overall, the firm remains positive regarding its cash flow and operational plans.

Feb 25, 2025

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

Kiniksa Pharmaceuticals announced its plan to develop KPL-387 for recurrent pericarditis, initiating a Phase 2/3 clinical trial by mid-2025. The company highlighted promising Phase 1 data suggesting that KPL-387 may allow for monthly subcutaneous dosing. Additionally, Kiniksa is shifting focus to cardiovascular indications and will discontinue the development of abiprubart for Sjögren's Disease. The company has also generated substantial revenue from its existing therapy ARCALYST since its launch in 2021.

Feb 20, 2025

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Kiniksa Pharmaceuticals announced that it will host a conference call on February 25, 2025, to report its fourth quarter and full year 2024 financial results. The call will include details on recent portfolio execution and will be available via live webcast. Kiniksa, focused on developing therapies for cardiovascular and autoimmune diseases, emphasizes its commitment to addressing unmet medical needs. Interested individuals can register for the call and access a replay on the company’s website afterward.

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance - ARCALYST (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-o

Kiniksa Pharmaceuticals has reported preliminary unaudited net product revenue for ARCALYST (rilonacept), forecasting $416.4 million for 2024, reflecting a 79% increase year-over-year. For 2025, the company anticipates net product revenue to be between $560 million and $580 million. Kiniksa also emphasizes its commitment to remaining cash flow positive annually while continuing to advance its clinical portfolio. These developments indicate a strong revenue trajectory for Kiniksa as it executes its commercial strategy.

Jan 6, 2025

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13, 2025. The presentation will showcase the company's efforts in developing therapeutic medicines for significant unmet medical needs. A live webcast of the event will be available through Kiniksa's website, with a replay accessible 48 hours post-event.

Nov 26, 2024

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced that its management will join a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024. The event will begin at 9:35 a.m. Eastern Time, with a live webcast available on Kiniksa's website. Following the presentation, a replay will be accessible approximately 48 hours later. Kiniksa focuses on developing therapeutic medicines for patients with significant unmet medical needs, particularly in autoimmune and cardiovascular conditions.

Nov 12, 2024

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

Kiniksa Pharmaceuticals International, plc is set to present at the 2024 Jefferies London Healthcare Conference on November 19, 2024. The management will engage in a fireside chat to discuss the company's therapeutic innovations and pipeline. A live webcast and a replay of the event will be available on Kiniksa's website. The company specializes in developing therapies for patients with serious diseases that currently have limited treatment options.

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution - ARCALYST (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth - - ARCALY

Kiniksa Pharmaceuticals announced its financial results for the third quarter of 2024, highlighting a notable 73% increase in net product revenue for ARCALYST, totaling $112.2 million. The company has adjusted its revenue expectations for ARCALYST upward to between $410 and $420 million for the year. Additionally, Kiniksa is prioritizing ongoing investments in marketing efforts and pipeline development while maintaining a positive cash flow. Despite a net loss of $12.7 million this quarter, an improvement over the previous year, operating expenses have risen due to collaboration and share-based compensation costs.

Oct 28, 2024

Kiniksa Pharmaceuticals Partners with GRAMMY Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis

Kiniksa Pharmaceuticals has partnered with Carly Pearce to enhance their Life DisRPted campaign aimed at raising awareness about recurrent pericarditis. This collaboration seeks to empower patients and caregivers by promoting early diagnosis and treatment of the condition. Carly Pearce, who was diagnosed with this chronic disease, will help highlight the impact it has on patients' lives. The campaign emphasizes the importance of recognizing symptoms and taking proactive steps towards effective care.

Oct 22, 2024

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced a conference call scheduled for October 29, 2024, at 8:30 a.m. Eastern Time. The call will focus on their third quarter 2024 financial results and updates on recent portfolio execution. Interested participants can join via telephone or through a live webcast, with a replay available on their website shortly after the event.

Aug 28, 2024

Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

Kiniksa Pharmaceuticals International, plc has announced its participation in the 2024 Wells Fargo Healthcare Conference scheduled for September 4, 2024. Management will engage in a fireside chat during the event, accessible via a live webcast on the company's website. Kiniksa focuses on developing medicines for patients with significant unmet medical needs, with promising immune-modulating assets under its portfolio.

Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution - ARCALYST (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth - - ARCAL

Kiniksa Pharmaceuticals announced its financial results for the second quarter of 2024, showing significant growth in ARCALYST net product revenue, which reached $103.4 million, marking a 90% increase year-over-year. The company forecasts 2024 net product revenue between $405 and $415 million, significantly higher than previous estimates. Kiniksa is also advancing its pipeline with the commencement of a Phase 2b clinical trial for Sjögren's Disease, a condition lacking FDA-approved therapies. Despite reporting a net loss for the quarter, Kiniksa anticipates remaining cash flow positive moving forward.

Jul 16, 2024

Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024

Kiniksa Pharmaceuticals International, plc will release its second quarter 2024 financial results and discuss its portfolio execution on July 23, 2024. The company will host a conference call and live webcast at 8:30 a.m. Eastern Time. Interested participants can register for the call and access a replay of the event shortly after it concludes. Kiniksa is focused on developing therapies for serious diseases with unmet medical needs, highlighting its immune-modulating assets.

Apr 23, 2024

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution - ARCALYST (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth - - ARCALYS

Kiniksa Pharmaceuticals reported strong financial results for Q1 2024, with net product revenue for ARCALYST reaching $78.9 million, reflecting an 85% increase from the previous year. The company has revised its revenue expectations upward for 2024, now anticipating net product sales of $370 to $390 million. Additionally, Kiniksa plans to start a Phase 2b trial for abiprubart in Sjögren's Disease in the second half of 2024. They expect to maintain a cash flow positive operating plan moving forward.

Apr 2, 2024

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart - Abiprubart Phase 2b trial in Sjogren's Disease planned to initiate in 2H 2024 - - Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further va

Kiniksa Pharmaceuticals has announced plans to initiate a Phase 2b clinical trial for abiprubart in Sjogren's Disease in the second half of 2024. This investigational therapy, a humanized anti-CD40 monoclonal antibody, aims to address an unmet need for patients with this debilitating condition. The company recently shared promising Phase 2 data showing the drug's efficacy in treating rheumatoid arthritis, reinforcing confidence in its potential across various autoimmune diseases. Kiniksa expects to fund the development of abiprubart through Phase 3 trials and maintain positive cash flow under its current operating plan.

Mar 29, 2024

From: Kiniksa Pharmaceuticals, Ltd. To: The holders of common shares of the Company

Kiniksa Pharmaceuticals, Ltd. has announced a proposal to redomicile from Bermuda to the UK through a scheme of arrangement. The move aims to provide a more advantageous legal and tax framework and aims to mitigate the potential adverse impacts of recent tax law changes and global initiatives. A directions hearing is set for April 19, 2024, where the Bermuda Supreme Court will provide directions for a shareholder meeting to vote on the scheme. The proposal requires approval from a majority of the shareholders and subsequent court sanctioning to be legally binding.

Feb 28, 2024

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution - ARCALYST (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 millio

Kiniksa Pharmaceuticals reported its financial results for the fourth quarter and full year of 2023, highlighting a net product revenue of $71.2 million for Q4 and $233.2 million for the full year. The company anticipates substantial growth in 2024, expecting revenues to reach between $360 million and $380 million. With cash reserves of $206.4 million, Kiniksa is well-positioned to fund operations through at least 2027. Significant updates in clinical trials and pipeline execution, particularly for ARCALYST and abiprubart, are expected in 2024.

Jan 4, 2024

Kiniksa Pharmaceuticals Provides Corporate Update - ARCALYST (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) - - ARCALYST 2024 net product revenue expected to be $360 - $380 m

Kiniksa Pharmaceuticals has reported a substantial increase in net product revenue for ARCALYST, with a growth of about 90% year-over-year, totaling approximately $233.1 million for 2023. The company anticipates revenue for 2024 to reach between $360 million and $380 million. Furthermore, Kiniksa's cash reserves are strong, projected to sustain operations through at least 2027. The Phase 2 trial for the rheumatoid arthritis treatment abiprubart has met its primary efficacy endpoint, with additional data expected in mid-2024.

Oct 31, 2023

Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution - ARCALYST (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth - - KPL-40

Kiniksa Pharmaceuticals reported its third quarter 2023 financial results, highlighting a substantial increase in net product revenue of $64.8 million, marking a 94% year-over-year growth. The company anticipates completing its Phase 2 clinical trial for KPL-404 in rheumatoid arthritis, with results expected in the first quarter of 2024. Additionally, the company has projected its cash reserves will sustain operations through at least 2027, supporting ongoing business and trial initiatives.

Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution - ARCALYST (rilonacept) Q2 2023 net product revenue of $54.5 million - - ARCALYST 2023 net product revenue guidance inc

Kiniksa Pharmaceuticals reported its second quarter 2023 financial results, highlighting a strong net product revenue of $54.5 million for ARCALYST. The company raised its full-year revenue guidance to between $220 million and $230 million, showcasing a significant year-over-year growth. Kiniksa is actively enrolling patients for its KPL-404 Phase 2 trial for rheumatoid arthritis, with results anticipated in early 2024. Additionally, the company has reinforced its financial stability with cash reserves expected to support operations until at least 2027.

Feb 28, 2023

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution - ARCALYST (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 millio

Kiniksa Pharmaceuticals reported its financial results for the fourth quarter and full year 2022, highlighting net product revenues of $39.9 million and $122.5 million, respectively. The company anticipates ARCALYST revenue to reach between $190 million and $205 million in 2023, reflecting over 60% growth compared to the previous year. Kiniksa is also focused on expanding its cardiovascular and autoimmune portfolio, with an emphasis on KPL-404's Phase 2 trial for rheumatoid arthritis expected to yield data in the first half of 2024. The company's cash reserves are projected to support operations into at least 2025.

Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update - ARCALYST (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively (unaudited) - - 2 of 3 cohorts enro

Kiniksa Pharmaceuticals announced a corporate and portfolio update showcasing net product revenues of $39.9 million and $122.5 million for Q4 2022 and full-year 2022, respectively. The company is currently advancing its clinical trial for KPL-404 in rheumatoid arthritis, with data anticipated in the first half of 2024. They project their cash reserves will support operations at least until 2025, underlining their strong financial positioning.

Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update - ARCALYST (rilonacept) Q3 2022 net revenue of $33.4 million - - RHAPSODY long-term extension data demonstrated rilonacep

Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update ARCALYST (rilonacept) Q3 2022 net revenue of $33.4 million - RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response

Aug 3, 2022

▲ +7.1%on this news· ran to +30% by day 3

Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update - ARCALYST (rilonacept) net revenue of $27.0 million in Q2 2022 - - ARCALYST full-year 2022 net revenue expected to be $

Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update ARCALYST (rilonacept) net revenue of $27.0 million in Q2 2022 - ARCALYST full-year 2022 net revenue expected to be $115 - $130 million - - Upfront and near-term proceeds of $10

Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update - ARCALYST (rilonacept) net revenue of $22.2 million in Q1 2022 - - ARCALYST full-year 2022 net revenue expected to be $1

Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (rilonacept) net revenue of $22.2 million in Q1 2022 - - ARCALYST full-year 2022 net revenue expected to be $115 - $130 million - - Cash reserves expected to fund operations i

Feb 22, 2022

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update - ARCALYST (rilonacept) net revenue of $18.7 million in Q4 2021 and $38.5 million in 2021 - - ARCALYST col

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update collaboration achieved profitability in Q4 2021 - ARCALYST full-year 2022 net revenue expected to be $115 - $130 million - Strategic collaboration with Huadong Me

Jan 10, 2022

Kiniksa Provides Corporate Update and Outlines Anticipated 2022 Milestones - ARCALYST full-year 2022 guidance to be provided with Q4 2021 financial results - - Vixarelimab Phase 2b data in prurigo nodularis expected in 2

Kiniksa Provides Corporate Update and Outlines Anticipated 2022 Milestones full-year 2022 guidance to be provided with Q4 2021 financial results - - Vixarelimab Phase 2b data in prurigo nodularis expected in 2H 2022 - - KPL-404 Phase 2 trial in rheumatoid arthritis now enro

Nov 1, 2021

▲ +22.5%on this news· ran to +46% by day 1

Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution - Q3 2021 ARCALYST (rilonacept) net revenue of $12.1 million - - ARCALYST prescribed by more than 200 physicians for rec

Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution - Q3 2021 ARCALYST (rilonacept) net revenue of $12.1 million - - ARCALYST prescribed by more than 200 physicians for recurrent pericarditis since approval - - Data from Phase

Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity - Q2 2021 ARCALYST (rilonacept) net revenue of $7.7 million with greater than 100 prescribing physicians - - Phase 3 data

Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity - Q2 2021 ARCALYST (rilonacept) net revenue of $7.7 million with greater than 100 prescribing physicians - - Phase 3 data from mavrilimumab clinical trial in COVID-19-related AR

May 4, 2021

Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity - ARCALYST (rilonacept) launched as the first and only FDA-approved therapy for recurrent pericarditis - - Mavrilimumab Pha

First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity ARCALYST (rilonacept) launched as the first and only FDA-approved therapy for recurrent pericarditis - Mavrilimumab Phase 2 severe COVID-19 data demonstrated a reduction in mechanical ventilation a

Feb 23, 2021

Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity - Strong execution across pipeline of immune-modulating assets throughout 2020 enables multiple milestones in 2021 -

Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity - Strong execution across pipeline of immune-modulating assets throughout 2020 enables multiple milestones in 2021 - - Rilonacept in recurrent pericarditis granted prior

Jan 11, 2021

Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones - PDUFA goal date of

Highlights Corporate Priorities and Expected 2021 Milestones PDUFA goal date of March 21, 2021 for rilonacept in recurrent pericarditis - Data from Phase 2 portion of mavrilimumab Phase 2/3 trial in severe COVID-19 pneumonia and hyperinflammation expected in 1H 2021 Final Phas

Nov 5, 2020

Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity - Rilonacept commercial launch in recurrent pericarditis anticipated in 1H 2021, if approved by the FDA - Mavrili

Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity - November 5, 2020 - Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pa

Oct 26, 2020

Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020 - Mavrilimumab reduced time-to

Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020 BERMUDA - October 26, 2020 - Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"),

Jul 30, 2020

Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity - Rilonacept pivotal Phase 3 trial in recurrent pericarditis met statistical significance for primary and all ma

Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity - July 30, 2020 - Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing

Jun 29, 2020

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY) - Primary and all major secondary efficacy endpoints were highly statistically significant - Rilonacept treatment resu

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY) - Primary and all major secondary efficacy endpoints were highly statistically significant - Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis

Apr 28, 2020

Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity - Financial guidance and clinical timelines for rilonacept, mavrilimumab, vixarelimab and KPL-404 remain intact a

Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity - April 28, 2020 - Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeu

Apr 22, 2020

Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint - Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numer

Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint BERMUDA - April 22, 2020 - Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and com

Feb 26, 2020

Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity - Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 - - Year-end

Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 - Year-end 2019 cash reserves of $233 million - - February 26, 2020 - Kiniksa

Jan 13, 2020

Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts - Enrollment target achieved for rilonacept Phase 3 trial in recurrent pericarditis; top-line data expected in 2H 2020 - - Enrollment target

Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts - Enrollment target achieved for rilonacept Phase 3 trial in recurrent pericarditis; top-line data expected in 2H 2020 - - Enrollment target achieved for mavrilimumab Phase 2 trial in giant cell arteritis; t

Oct 28, 2019

Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 Operating plan

Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 Operating plan funded into 2H 2021; no current plan to raise additional c

Aug 12, 2019

Kiniksa Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity Rilonacept pivotal Phase 3 study dosing patients in the U.S., Australia, Israel and Italy; expect to present fin

Kiniksa Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity Rilonacept pivotal Phase 3 study dosing patients in the U.S., Australia, Israel and Italy; expect to present final Phase 2 data this year Mavrilimumab global Phase 2 stud

May 16, 2019

Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research

HAMILTON, Bermuda, May 16, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, will

May 2, 2019

Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity First patient dosed in Phase 2a trial of KPL-716 in prurigo nodularis Upcoming presentations at SID, ISPOR and EU

Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity First patient dosed in Phase 2a trial of KPL-716 in prurigo nodularis Upcoming presentations at SID, ISPOR and EULAR scientific conferences on KPL-716, rilonacept and mav

Mar 7, 2019

Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity Enrollment and dosing of patients commenced in rilonacept pivotal Phase 3 trial Enrollment and dos

Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity Enrollment and dosing of patients commenced in rilonacept pivotal Phase 3 trial Enrollment and dosing of patients commenced in mavrilimumab global Phase 2 t

Jan 28, 2019

Every Second Counts January 2019 Forward Looking Statements This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements within the mea

Every Second Counts January 2019 Forward Looking Statements This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 199

Nov 1, 2018

Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress Rilonacept pivotal Phase 3 clinical trial initiating this year Mavrilimumab pre-IND meeting complete; plans for global Phase 2 clinical trial adv

Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress Rilonacept pivotal Phase 3 clinical trial initiating this year Mavrilimumab pre-IND meeting complete; plans for global Phase 2 clinical trial advancing KPL-716 advancing into multiple chronic pruritic d

Sep 15, 2018

Kiniksa Presents KPL-716 Clinical Data at the 27 th European Academy of Dermatology and Venereology -Single-doses were well-tolerated and showed reduction in pruritus - - Data support plans for advancement into multiple

Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology -Single-doses were well-tolerated and showed reduction in pruritus - - Data support plans for advancement into multiple chronic pruritic diseases, including prurigo nodularis - H

Sep 13, 2018

th EADV Congress, Late-Breaker Abstract, KPL-716-C001 (Phase 1a/1b) Authors: Zamaneh Mikhak 1 , Joel M. Neutel 2 , Robert Bissonnette 3 , Dareen Siri 4 , Thomas Wade 5 , Stephen K. Tyring 6 , Eben Tessari 1 , Rohan Gandh

27th EADV Congress, Late-Breaker Abstract, KPL-716-C001 (Phase 1a/1b) Authors: Zamaneh Mikhak1, Joel M. Neutel2, Robert Bissonnette3, Dareen Siri4, Thomas Wade5, Stephen K. Tyring6, Eben Tessari1, Rohan Gandhi1, Fang Fang1, John F. Paolini1 Author Affiliations: 1. Kiniksa Pharm

Aug 6, 2018